JOHN M. LEONARD - 23 Aug 2021 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
President and CEO, Director
Signature
/s/Glenn Goddard Attorney-In-Fact
Issuer symbol
NTLA
Transactions as of
23 Aug 2021
Transactions value $
-$3,761,754
Form type
4
Filing time
25 Aug 2021, 16:14:17 UTC
Previous filing
20 Aug 2021
Next filing
01 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Options Exercise $364K +27.1K +3.77% $13.40 746K 23 Aug 2021 Direct
transaction NTLA Common Stock Sale -$2.86M -18.9K -2.53% $151.54 728K 23 Aug 2021 Direct F1, F2
transaction NTLA Common Stock Sale -$1.25M -8.17K -1.12% $153.08 719K 23 Aug 2021 Direct F1, F3
transaction NTLA Common Stock Sale -$15.4K -100 -0.01% $153.52 719K 23 Aug 2021 Direct F1
holding NTLA Common Stock 58.4K 23 Aug 2021 By Trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock Option (right to buy) Options Exercise $0 -27.1K -10.8% $0.00 224K 23 Aug 2021 Common Stock 27.1K $13.40 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.38 to $152.18, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.38 to $153.12, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.
F4 Shares held by the John M. Leonard 2015 Irrevocable Trust.
F5 The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 134,583 shares as of August 23, 2021.